FDA Approves Innovative Oral Cholesterol Medication by Merck

The FDA's approval of Lipfendra, a new oral medication for high-risk cholesterol patients, represents a significant advancement in cardiovascular treatment options. This non-injectable alternative could improve adherence to treatment regimens and reduce healthcare costs. The drug's ability to significantly lower LDL cholesterol levels may have a positive impact on public health.